## Draft - June 21, 2021

## MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention Atlanta, Georgia 30329 June 23-25, 2021

## PRESIDER/PRESENTER(s)

		PRESIDER/PRESENTER(s)
Wednesda	ıy, June 23, 202 <u>1</u>	
11:00	Welcome & Introductions	Dr. José Romero (ACIP Chair)
		Dr. Amanda Cohn (ACIP Executive Secretary, CDC)
11:30	Coronavirus Disease 2019 (COVID-19) Vaccines	
	Introduction	Dr. Matthew Daley (ACIP, WG Chair)
	Overview of myocarditis and pericarditis	Dr. Matthew Oster (CDC/NCBDDD)
	Update on COVID-19 vaccine safety, including myocarditis after mRNA vaccines	Dr. Tom Shimabukuro (CDC/NCEZID)
	V <sub>2</sub> CT	De Care Lee (ACID MeCT Constraint)
12.45	VaST assessment	Dr. Grace Lee (ACIP, VaST Co-chair)
12:45 1:00	Break COVID 10 mBNA vascines in adelescents and voung adults; honefit rick discussion	Dr. Magan Wallaca (CDC/NCIRD)
1.00	COVID-19 mRNA vaccines in adolescents and young adults: benefit-risk discussion	Dr. Megan Wallace (CDC/NCIRD)
	Discussion	
2:15	Break	
2:30	Public Comment	
3:00	Overview of data to inform recommendations for additional doses of COVID-19	Dr. Sara Oliver (CDC/NCIRD)
	vaccines	
	Discussion	
4:00	Adjourn	
Thursday,	June 24, 2021	
10:00	Welcome & Introductions	Dr. José Romero (ACIP Chair)
		Dr. Amanda Cohn (ACIP Executive Secretary, CDC)
10:30	Dengue Vaccine	
	Introduction	Dr. Wilbur Chen (ACIP, WG Co-Chair)
	Acceptability of dengue vaccine in Puerto Rico	Dr. Ines Esquilin (University of Puerto Rico, School of Medicine)
	Implementation of dengue vaccine in Puerto Rico	Dr. Iris Cardona (Department of Health, Puerto Rico)
	Dengue vaccine draft recommendations using the evidence to recommendation	Dr. Gabriela Paz-Bailey (CDC/NCEZID)
	framework	
	Dengue VFC Resolution	Dr. Jeanne Santoli (CDC/NCIRD)
12:20	Break	
12:30	Influenza Vaccines Introduction	Dr. Keinn Talhet (ACID, W.G. Chair)
	Flucelvax Quadrivalent (ccIIV4) Phase III Randomized Controlled	Dr. Keipp Talbot (ACIP, WG Chair) Dr. Gregg Sylvester (Seqirus)
	Trial—Immunogenicity and Safety in Children 6 through 47 months	Dr. Gregg Sylvester (Sequius)
	Work group considerations and proposed recommendations for the 2021-22	Dr. Lisa Grohskopf (CDC/NCIRD)
	Influenza Season	Dr. Lisa dronskopi (CDC/NCIND)
	Updates to Influenza VFC Resolution	Dr. Jeanne Santoli (CDC/NCIRD)
2:10	Break	
2:20	Rabies Vaccines	
	Introduction	Dr. Sharon Frey (ACIP, WG Chair)
	Rabies immune globulin	Dr. Agam Rao (CDC/NCEZID)
	Rabies post-exposure prophylaxis schedule	Dr. Agam Rao (CDC/NCEZID)
	Rabies pre-exposure prophylaxis: GRADE/EtR summary	Dr. Agam Rao (CDC/NCEZID)
3:40	Break	J (, /
3:45	Public Comment	
4:15	Break	
4:20	Votes and VFC Votes	
	Dengue Vaccine	Dr. Gabriela Paz-Bailey (CDC/NCEZID)
	Dengue Vaccine (VFC)	Dr. Jeanne Santoli (CDC/NCIRD)
	Influenza Vaccines	Dr. Lisa Grohskopf (CDC/NCIRD)
	Influenza Vaccine (VFC)	Dr. Jeanne Santoli (CDC/NCIRD)
	Rabies Vaccines	Dr. Agam Rao (CDC/NCEZID)
5:15	Adjourn	S ABUIL INDO (CDC) NCLLID)
3.13	лијони	

Friday, June 25, 2021

10:00 Welcome & Introductions Dr. José Romero (ACIP Chair)

Dr. Amanda Cohn (ACIP Executive Secretary, CDC)

10:15 Zoster Vaccines

Introduction Dr. Grace Lee (ACIP, WG Chair)
Burden of herpes zoster in immunocompromised adults Dr. Tara Anderson (CDC/NCIRD)
Use of recombinant zoster vaccine in immunocompromised populations: overview of Ms. Robyn Widenmaier (GSK)

clinical program

11:05 Pneumococcal Vaccines

Introduction
Updates on epidemiology of invasive pneumococcal disease in U.S. adults

Cost effectiveness of PCV15 and PCV20 use in U.S. adults
GRADE for age-based PCV15 and PCV20 use in U.S. adults
EtR summary of age-based PCV15 and PCV20 use in U.S. adults

Summary and Timeline

1:00 Adjourn

Dr. Kathy Poehling (ACIP, WG Chair) Mr. Ryan Gierke (CDC/NCIRD)

Dr. Charles Stoecker (Tulane University)
Ms. Jennifer Farrar (CDC/NCIRD)
Dr. Miwako Kobayashi (CDC/NCIRD)
Dr. Miwako Kobayashi (CDC/NCIRD)

Acronyms

CDC Centers for Disease Control and Prevention
CMS Centers for Medicare and Medicaid Services

COVID-19 Coronavirus Disease 2019

EtR Evidence to Recommendations Framework

FDA Food and Drug Administration

GRADE Grading of Recommendations Assessment, Development and Evaluation

HRSA Health Resources and Services Administration

IHS Indian Health Service

NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/DDID]

NCIRD National Center for Immunization & Respiratory Diseases [of CDC/DDID]

NCEZID National Center for Emerging and Zoonotic Diseases [of CDC/DDID]

NIAID National Institute of Allergy and Infectious Diseases
OIDP Office of Infectious Disease and HIV/AIDS Policy
PCV15 15-Valent Pneumococcal Conjugate Vaccine
PCV20 20-Valent Pneumococcal Conjugate Vaccine
SARS-COV-2 Severe Acute Respiratory Syndrome Coronavirus 2

WG Work Group

WHO World Health Organization VE Vaccine Effectiveness